SCHEMBL5991960

SCHEMBL5991960

CCOC(=O)C(Cc1ccc(OCCc2ccc(C#N)cc2)cc1)Sc1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 8/20 0.45
PPARD Q03181 3/20 0.45
PPARG P37231 9/20 0.45
ALOX5 P09917 7/20 0.45
PTGES O14684 5/20 0.45
FFAR1 O14842 1/20 0.44
ABCB1 P08183 1/20 0.41
HPGD P15428 1/20 0.41
ABCG2 Q9UNQ0 1/20 0.41
TDP1 Q9NUW8 1/20 0.40
MAOB P27338 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6821028 0.89 PPARG (0.47) PPARAPPARDPPARGALOX5PTGES
SCHEMBL5992070 0.88 PPARG (0.50) PPARAPPARDPPARGALOX5PTGES
SCHEMBL6821601 0.85 PPARG (0.48) PPARAPPARDPPARGALOX5PTGES
SCHEMBL5991976 0.78 PPARA (0.56) PPARAPPARDPPARG
SCHEMBL5992755 0.76 MMP8 (0.45) PPARG
SCHEMBL7243191 0.76 PPARG (0.52) PPARAPPARGALOX5PTGESFFAR1
SCHEMBL5992817 0.74 PPARA (0.56) PPARAPPARDPPARGFFAR1
SCHEMBL5992824 0.74 PPARA (0.56) PPARAPPARDPPARGFFAR1
SCHEMBL947174 0.72 FFAR1 (0.55) PPARAPPARDPPARGFFAR1TDP1
SCHEMBL3714917 0.71 MAOB (0.68) PPARAPPARDFFAR1ABCB1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060173204-A1 New 3-aryl propionic acid derivatives and analogs ANDERSSON KJELL 2006-08-03 US disclosed
US-20040229949-A1 New 3-aryl propionic acid derivatives and analogs ANDERSSON KJELL (SE) 2004-11-18 US disclosed
US-6630600-B1 Intermediate for their manufacture, pharmaceutical preparations containing them and the use of the compounds in clinical conditions associated with insulin resistance. ASTRAZENECA AB (SE) 2003-10-07 US disclosed
EP-1084102-B1 NEW 3-ARYL PROPIONIC ACID DERIVATIVES AND ANALOGS ASTRAZENECA AB (SE) 2003-10-01 EP disclosed
EP-1084102-A1 NEW 3-ARYL PROPIONIC ACID DERIVATIVES AND ANALOGS AstraZeneca AB (SE) 2001-03-21 EP disclosed
WO-1999062871-A1 NEW 3-ARYL PROPIONIC ACID DERIVATIVES AND ANALOGS ASTRAZENECA AB (SE) 1999-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040229949-A1 New 3-aryl propionic acid derivatives and analogs GPR119, INSR, IRS1 PPARA 11/4885PPARD 8/4885PPARG 22/4885
US-20060173204-A1 New 3-aryl propionic acid derivatives and analogs GPR119, INSR, IRS1 PPARA 11/4885PPARD 8/4885PPARG 22/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.